Related references
Note: Only part of the references are listed.Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
Ziming Wang et al.
NATURE MEDICINE (2019)
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilie et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma
Camille Guillerey et al.
BLOOD (2018)
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee et al.
BLOOD (2018)
Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor
Alexander D. Barrow et al.
CELL (2018)
NKG2D and its ligands in cancer
Payal Dhar et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient
David A. Sallman et al.
HAEMATOLOGICA (2018)
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal A. Patel et al.
IMMUNITY (2018)
Current strategies exploiting NK-cell therapy to treat haematologic malignancies
Jenna K. Johnson et al.
INTERNATIONAL JOURNAL OF IMMUNOGENETICS (2018)
Genetics of Natural Killer Cells in Human Health, Disease, and Survival
Peter Parham et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 36 (2018)
Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells
Yali Han et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Frontline Science: IL-18 primes murine NK cells for proliferation by promoting protein synthesis, survival, and autophagy
Yosif El-Darawish et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2018)
Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells
Quirin Hammer et al.
NATURE IMMUNOLOGY (2018)
Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion
Lyndsay Avery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity
Lucas Ferrari de Andrade et al.
SCIENCE (2018)
Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned
Jeanette E. Boudreau et al.
TRENDS IN IMMUNOLOGY (2018)
Identification of the fungal ligand triggering cytotoxic PRR-mediated NK cell killing of Cryptococcus and Candida
Shu Shun Li et al.
NATURE COMMUNICATIONS (2018)
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient
David A. Sallman et al.
HAEMATOLOGICA (2018)
Adaptive Natural Killer Cells Integrate Interleukin-18 during Target-Cell Encounter
Quirin Hammer et al.
FRONTIERS IN IMMUNOLOGY (2018)
Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade
Simone A. Minnie et al.
BLOOD (2018)
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Michal A. Stanczak et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Joy Hsu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
Nadine van Montfoort et al.
CELL (2018)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre et al.
CELL (2018)
Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Frederike Bensch et al.
NATURE MEDICINE (2018)
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
Marcus Ruscetti et al.
SCIENCE (2018)
NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma
Tobias Weiss et al.
CANCER RESEARCH (2018)
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Amy K. Erbe et al.
CLINICAL CANCER RESEARCH (2018)
Dysregulated cellular functions and cell stress pathways provide critical cues for activating and targeting natural killer cells to transformed and infected cells
David H. Raulet et al.
IMMUNOLOGICAL REVIEWS (2017)
Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
Silvia Pesce et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
Julia A. Wagner et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation
Jeanette E. Boudreau et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity
Martina Molgora et al.
NATURE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy
Zachary B. Davis et al.
SEMINARS IN IMMUNOLOGY (2017)
Tailoring Natural Killer cell immunotherapy to the tumour microenvironment
Alexander David Barrow et al.
SEMINARS IN IMMUNOLOGY (2017)
Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer
Jiaying Shen et al.
CELL DEATH & DISEASE (2017)
Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma
Reed Friend et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Decreased expression of the NKG2D ligand ULBP4 may be an indicator of poor prognosis in patients with nasopharyngeal carcinoma
Yuanji Xu et al.
ONCOTARGET (2017)
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
Caroline Lonez et al.
BMJ OPEN (2017)
Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
Jorg U. Schmohl et al.
CANCER RESEARCH AND TREATMENT (2017)
Endothelial cells express NKG2D ligands and desensitize antitumor NK responses
Thornton W. Thompson et al.
ELIFE (2017)
Interferon Gamma induces changes in Natural Killer (NK)Cell Ligand Expression and Alter NK Cell-Mediated and Alters NK Cell-Mediated Lysis of pediatric Cancer Cell Lines
Arianexys Aquino-Lopez et al.
FRONTIERS IN IMMUNOLOGY (2017)
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy
Amy K. Erbe et al.
FRONTIERS IN IMMUNOLOGY (2017)
Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma
Sandra Weil et al.
FRONTIERS IN IMMUNOLOGY (2017)
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
Jingyu Zhang et al.
SCIENCE ADVANCES (2017)
Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer
Stefanie Aust et al.
SCIENTIFIC REPORTS (2017)
MHC-I Genotype Restricts the Oncogenic Mutational Landscape
Rachel Marty et al.
CELL (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells
Lucia Fernandez et al.
CLINICAL CANCER RESEARCH (2017)
Innate Immunity to Intracellular Pathogens: Balancing Microbial Elimination and Inflammation
Gabriel Mitchell et al.
CELL HOST & MICROBE (2017)
Paired Siglec receptors generate opposite inflammatory responses to a humanspecific pathogen
Flavio Schwarz et al.
EMBO JOURNAL (2017)
CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT
F. Cichocki et al.
LEUKEMIA (2016)
Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+Colorectal Cancer Cells
J. U. Schmohl et al.
TARGETED ONCOLOGY (2016)
Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
Dhifaf Sarhan et al.
CANCER RESEARCH (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
SLAM family receptors in normal immunity and immune pathologies
Ning Wu et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma
Christopher J. Forlenza et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
NKG2D-NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo
Saravanan Raju et al.
JOURNAL OF IMMUNOLOGY (2016)
CIS is a potent checkpoint in NK cell-mediated tumor immunity
Rebecca B. Delconte et al.
NATURE IMMUNOLOGY (2016)
Siglec-7 Defines a Highly Functional Natural Killer Cell Subset and Inhibits Cell-Mediated Activities
J. -Y. Shao et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2016)
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
Rizwan Romee et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Immunological Mechanisms Underneath the Efficacy of Cancer Therapy
Lorenzo Galluzzi et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Margaretha G. M. Roemer et al.
CANCER IMMUNOLOGY RESEARCH (2016)
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Shannon L. Maude et al.
BLOOD (2015)
Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors
Shengjun Lu et al.
CLINICAL CANCER RESEARCH (2015)
The Inhibitory Receptor NKG2A Sustains Virus-Specific CD8+ T Cells in Response to a Lethal Poxvirus Infection
Aaron S. Rapaport et al.
IMMUNITY (2015)
Selection, tuning, and adaptation in mouse NK cell education
Nadir Kadri et al.
IMMUNOLOGICAL REVIEWS (2015)
Co-evolution of MHC class I and variable NK cell receptors in placental mammals
Lisbeth A. Guethlein et al.
IMMUNOLOGICAL REVIEWS (2015)
Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
Liyun Xu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction
Claudia A. Nold-Petry et al.
NATURE IMMUNOLOGY (2015)
Interferon-gamma regulates cellular metabolism and mRNA translation to potentiate macrophage activation
Xiaodi Su et al.
NATURE IMMUNOLOGY (2015)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
Weiwen Deng et al.
SCIENCE (2015)
NKG2D Receptor and Its Ligands in Host Defense
Lewis L. Lanier
CANCER IMMUNOLOGY RESEARCH (2015)
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Yu-Hwa Huang et al.
NATURE (2015)
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
Michelle K. Gleason et al.
BLOOD (2014)
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function
Robert J. Johnston et al.
CANCER CELL (2014)
NKG2D CARs as Cell Therapy for Cancer
Charles L. Sentman et al.
CANCER JOURNAL (2014)
Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance
Camilla Jandus et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Correction: Cellular Expression, Trafficking, and Function of Two Isoforms of Human ULBP5/RAET1G
Robert A. Eagle et al.
PLoS One (2014)
Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
Ines Pires da Silva et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Reversal of natural killer cell exhaustion by TIM-3 blockade
Anne Gallois et al.
ONCOIMMUNOLOGY (2014)
Regulation of Ligands for the NKG2D Activating Receptor
David H. Raulet et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
Rizwan Romee et al.
BLOOD (2013)
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Shauna M. Collins et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
Sylvie Rusakiewicz et al.
CANCER RESEARCH (2013)
A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells
Yu-Hsiang Chang et al.
CANCER RESEARCH (2013)
Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells
S. Liu et al.
CELL DEATH AND DIFFERENTIATION (2013)
Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy
Q. Zhou et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
ASC Controls IFN-γ Levels in an IL-18-Dependent Manner in Caspase-1-Deficient Mice Infected with Francisella novicida
Roberto Pierini et al.
JOURNAL OF IMMUNOLOGY (2013)
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
Taku Okazaki et al.
NATURE IMMUNOLOGY (2013)
TIM-3 Does Not Act as a Receptor for Galectin-9
Judith Leitner et al.
PLOS PATHOGENS (2013)
The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells
Shamaila Munir et al.
ONCOIMMUNOLOGY (2013)
Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function
Bree Foley et al.
BLOOD (2012)
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
Lishomwa C. Ndhlovu et al.
BLOOD (2012)
Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9
Michelle K. Gleason et al.
BLOOD (2012)
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
Nidale Tarek et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice
Helge Frebel et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
A Structural Basis for Antigen Presentation by the MHC Class Ib Molecule, Qa-1b
Li Zeng et al.
JOURNAL OF IMMUNOLOGY (2012)
Inhibitory Receptors on Lymphocytes: Insights from Infections
Pamela M. Odorizzi et al.
JOURNAL OF IMMUNOLOGY (2012)
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
Michelle K. Gleason et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
Shigeki Chiba et al.
NATURE IMMUNOLOGY (2012)
Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion
Manu Rangachari et al.
NATURE MEDICINE (2012)
CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
Rebecca Waitz et al.
ONCOIMMUNOLOGY (2012)
Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1
Yuk Pheel Park et al.
BLOOD (2011)
Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models
Maria Teresa Sabrina Bertilaccio et al.
BLOOD (2011)
Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways
Judong Lee et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
Expansion of a unique CD57+ NKG2Chi natural killer cell subset during acute human cytomegalovirus infection
Sandra Lopez-Verges et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Lucy S. K. Walker et al.
NATURE REVIEWS IMMUNOLOGY (2011)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes
Jennifer A. Belisle et al.
MOLECULAR CANCER (2010)
An six-amino acid motif in the α3 domain of MICA is the cancer therapeutic target to inhibit shedding
Xuanjun Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
Alessandra Soriani et al.
BLOOD (2009)
Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLAexhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation
Junli Yu et al.
BLOOD (2009)
Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation
Masafumi Nakayama et al.
BLOOD (2009)
NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for Immunoediting
Roger W. McGilvray et al.
CLINICAL CANCER RESEARCH (2009)
Comparative genomics indicates the mammalian CD33rSiglec locus evolved by an ancient large-scale inverse duplication and suggests all Siglecs share a common ancestral region
Huan Cao et al.
IMMUNOGENETICS (2009)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Lack of CD200 Enhances Pathological T Cell Responses during Influenza Infection
Tomasz P. Rygiel et al.
JOURNAL OF IMMUNOLOGY (2009)
The Essential Role of Single Ig IL-1 Molecule/Toll IL-1R8 in Regulation Immune Response
Katarzyna Bulek et al.
JOURNAL OF IMMUNOLOGY (2009)
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Noa Stanietsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
TNFR1 signaling and IFN-γ signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis
Nele Mueller-Hermelink et al.
CANCER CELL (2008)
FcγRIIIa expression is not increased on natural killer cells expressing the FcγRIIIa-158V allotype
Nicolas Congy-Jolivet et al.
CANCER RESEARCH (2008)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
Eric D. Hsi et al.
CLINICAL CANCER RESEARCH (2008)
SIGLEC16 encodes a DAP12-associated receptor expressed in macrophages that evolved from its inhibitory counterpart SIGLEC11 and has functional and non-functional alleles in humans
Huan Cao et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma
Amorette Barber et al.
EXPERIMENTAL HEMATOLOGY (2008)
Four novel ULBP splice variants are ligands for human NKG2D
Wei Cao et al.
INTERNATIONAL IMMUNOLOGY (2008)
Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells
Ana C. Anderson et al.
SCIENCE (2007)
Host immune system gene targeting by a viral miRNA
Noam Stern-Ginossar et al.
SCIENCE (2007)
Donor natural killer cell allorecognition of missing self in haploidentical hernatopoietic transplantation for acute myeloid leukemia: challenging its predictive value
Loredana Ruggeri et al.
BLOOD (2007)
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT
Jeffery S. Miller et al.
BLOOD (2007)
Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands
Brett K. Kaiser et al.
NATURE (2007)
Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer
Arnorette Barber et al.
CANCER RESEARCH (2007)
The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis
Hui Xiao et al.
IMMUNITY (2007)
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Arlene H. Sharpe et al.
NATURE IMMUNOLOGY (2007)
Human NK cell education by inhibitory receptors for MHC class I
Nicolas Anfossi et al.
IMMUNITY (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion
YT Bryceson et al.
BLOOD (2006)
The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cγ signaling pathways in human NK cells
I Tassi et al.
JOURNAL OF IMMUNOLOGY (2005)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C Zhu et al.
NATURE IMMUNOLOGY (2005)
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
S Gasser et al.
NATURE (2005)
Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo
K Wiemann et al.
JOURNAL OF IMMUNOLOGY (2005)
SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4-mediated signaling through different mechanisms
JZ Qin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes
KC Hsu et al.
BLOOD (2005)
Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family
C Garlanda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D
L Bacon et al.
JOURNAL OF IMMUNOLOGY (2004)
Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming
A Martín-Fontecha et al.
NATURE IMMUNOLOGY (2004)
Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule
C Bottino et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
V Groh et al.
NATURE (2002)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
ULBPs, novel MHC class I-related molecules bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor
D Cosman et al.
IMMUNITY (2001)
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population
K Imai et al.
LANCET (2000)
Cytolytic mechanisms and expression of activation-regulating receptors on effector-type CD8+CD45RA+CD27- human T cells
PA Baars et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
